BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,550,000 shares, an increase of 9.4% from the December 15th total of 2,330,000 shares. Based on an average daily volume of 806,600 shares, the days-to-cover ratio is currently 3.2 days.

BioNTech Stock Performance

Shares of BNTX stock traded down $0.83 during trading hours on Friday, reaching $111.93. The stock had a trading volume of 458,339 shares, compared to its average volume of 565,513. The firm has a market capitalization of $26.83 billion, a PE ratio of -53.30 and a beta of 0.18. The firm has a 50-day simple moving average of $114.69 and a 200-day simple moving average of $104.41. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, equities analysts forecast that BioNTech will post -3.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Planning Capital Management Corp lifted its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the period. Blue Trust Inc. lifted its stake in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC boosted its holdings in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in BioNTech during the third quarter worth approximately $210,000. Finally, Probity Advisors Inc. acquired a new stake in BioNTech in the third quarter worth approximately $216,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BNTX. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.